vs

Side-by-side financial comparison of Bowhead Specialty Holdings Inc. (BOW) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Bowhead Specialty Holdings Inc. is the larger business by last-quarter revenue ($151.7M vs $151.7M, roughly 1.0× Tarsus Pharmaceuticals, Inc.). Bowhead Specialty Holdings Inc. runs the higher net margin — 9.8% vs -5.5%, a 15.3% gap on every dollar of revenue. Bowhead Specialty Holdings Inc. produced more free cash flow last quarter ($326.0M vs $13.0M).

Bowhead Specialty Holdings Inc. is a specialty insurance holding company that offers a diversified portfolio of property and casualty insurance products, focusing on underserved niche market segments primarily across North America. It provides tailored risk management solutions and specialized coverage options for both commercial and individual clients.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

BOW vs TARS — Head-to-Head

Bigger by revenue
BOW
BOW
1.0× larger
BOW
$151.7M
$151.7M
TARS
Higher net margin
BOW
BOW
15.3% more per $
BOW
9.8%
-5.5%
TARS
More free cash flow
BOW
BOW
$313.0M more FCF
BOW
$326.0M
$13.0M
TARS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BOW
BOW
TARS
TARS
Revenue
$151.7M
$151.7M
Net Profit
$14.8M
$-8.4M
Gross Margin
Operating Margin
11.7%
-5.3%
Net Margin
9.8%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.44
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOW
BOW
TARS
TARS
Q4 25
$151.7M
$151.7M
Q3 25
$143.9M
$118.7M
Q2 25
$133.3M
$102.7M
Q1 25
$122.7M
$78.3M
Q4 24
$66.4M
Q3 24
$116.8M
$48.1M
Q2 24
$98.9M
$40.8M
Q1 24
$27.6M
Net Profit
BOW
BOW
TARS
TARS
Q4 25
$14.8M
$-8.4M
Q3 25
$15.2M
$-12.6M
Q2 25
$12.3M
$-20.3M
Q1 25
$11.4M
$-25.1M
Q4 24
$-23.1M
Q3 24
$12.1M
$-23.4M
Q2 24
$5.5M
$-33.3M
Q1 24
$-35.7M
Operating Margin
BOW
BOW
TARS
TARS
Q4 25
11.7%
-5.3%
Q3 25
13.3%
-12.2%
Q2 25
11.9%
-21.6%
Q1 25
11.8%
-33.5%
Q4 24
-36.8%
Q3 24
13.5%
-52.3%
Q2 24
7.5%
-81.6%
Q1 24
-136.5%
Net Margin
BOW
BOW
TARS
TARS
Q4 25
9.8%
-5.5%
Q3 25
10.5%
-10.6%
Q2 25
9.3%
-19.8%
Q1 25
9.3%
-32.1%
Q4 24
-34.8%
Q3 24
10.4%
-48.7%
Q2 24
5.6%
-81.6%
Q1 24
-129.4%
EPS (diluted)
BOW
BOW
TARS
TARS
Q4 25
$0.44
$-0.17
Q3 25
$0.45
$-0.30
Q2 25
$0.36
$-0.48
Q1 25
$0.34
$-0.64
Q4 24
$-0.57
Q3 24
$0.36
$-0.61
Q2 24
$0.20
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOW
BOW
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$193.5M
$417.3M
Total DebtLower is stronger
$146.4M
$72.4M
Stockholders' EquityBook value
$448.3M
$343.4M
Total Assets
$2.4B
$562.2M
Debt / EquityLower = less leverage
0.33×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOW
BOW
TARS
TARS
Q4 25
$193.5M
$417.3M
Q3 25
$197.9M
$401.8M
Q2 25
$114.8M
$381.1M
Q1 25
$88.0M
$407.9M
Q4 24
$291.4M
Q3 24
$132.9M
$317.0M
Q2 24
$180.3M
$323.6M
Q1 24
$298.5M
Total Debt
BOW
BOW
TARS
TARS
Q4 25
$146.4M
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
BOW
BOW
TARS
TARS
Q4 25
$448.3M
$343.4M
Q3 25
$430.2M
$335.1M
Q2 25
$407.2M
$332.6M
Q1 25
$391.0M
$342.5M
Q4 24
$224.5M
Q3 24
$364.7M
$237.5M
Q2 24
$339.9M
$252.2M
Q1 24
$275.2M
Total Assets
BOW
BOW
TARS
TARS
Q4 25
$2.4B
$562.2M
Q3 25
$2.1B
$534.6M
Q2 25
$1.9B
$495.0M
Q1 25
$1.8B
$500.8M
Q4 24
$377.0M
Q3 24
$1.5B
$376.3M
Q2 24
$1.4B
$376.8M
Q1 24
$349.3M
Debt / Equity
BOW
BOW
TARS
TARS
Q4 25
0.33×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOW
BOW
TARS
TARS
Operating Cash FlowLast quarter
$331.6M
$19.3M
Free Cash FlowOCF − Capex
$326.0M
$13.0M
FCF MarginFCF / Revenue
214.9%
8.6%
Capex IntensityCapex / Revenue
3.7%
4.2%
Cash ConversionOCF / Net Profit
22.34×
TTM Free Cash FlowTrailing 4 quarters
$593.4M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOW
BOW
TARS
TARS
Q4 25
$331.6M
$19.3M
Q3 25
$114.7M
$18.3M
Q2 25
$109.0M
$-29.4M
Q1 25
$47.7M
$-20.7M
Q4 24
$-22.2M
Q3 24
$119.4M
$-8.7M
Q2 24
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
BOW
BOW
TARS
TARS
Q4 25
$326.0M
$13.0M
Q3 25
$113.5M
$16.3M
Q2 25
$107.4M
$-30.4M
Q1 25
$46.5M
$-21.2M
Q4 24
$-22.3M
Q3 24
$118.4M
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
BOW
BOW
TARS
TARS
Q4 25
214.9%
8.6%
Q3 25
78.8%
13.8%
Q2 25
80.6%
-29.6%
Q1 25
37.9%
-27.1%
Q4 24
-33.5%
Q3 24
101.4%
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
BOW
BOW
TARS
TARS
Q4 25
3.7%
4.2%
Q3 25
0.9%
1.6%
Q2 25
1.2%
1.0%
Q1 25
1.0%
0.8%
Q4 24
0.1%
Q3 24
0.9%
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
BOW
BOW
TARS
TARS
Q4 25
22.34×
Q3 25
7.56×
Q2 25
8.83×
Q1 25
4.18×
Q4 24
Q3 24
9.88×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons